NVSNovartis PharmaceuticalsSigning up patients
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy Secondary to Age-related Macular Degeneration
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 272 (planned)
- Started
- Mar 9, 2026
- Main results expected
- Aug 21, 2029
- Fully finished
- Aug 22, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change of geographic atrophy (GA) lesion area in the study eye
Measured over: From Baseline to Month 18
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","statusModule"]}
Trial ID NCT07441642 · record last updated 2026-11-09 · checked 2026-11-09 15:47 UTC